Needham & Company LLC Reaffirms Hold Rating for Omeros (NASDAQ:OMER)

Omeros (NASDAQ:OMER)‘s stock had its “hold” rating reiterated by equities research analysts at Needham & Company LLC in a research note issued on Friday,Benzinga reports.

Other equities research analysts have also recently issued reports about the company. D. Boral Capital reaffirmed a “buy” rating and set a $36.00 price target on shares of Omeros in a report on Thursday. RODMAN&RENSHAW raised shares of Omeros to a “strong-buy” rating in a report on Thursday, November 14th. Cantor Fitzgerald reiterated a “neutral” rating on shares of Omeros in a research report on Thursday, November 14th. StockNews.com upgraded Omeros from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. Finally, Rodman & Renshaw started coverage on Omeros in a report on Thursday, November 14th. They issued a “buy” rating and a $9.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $22.50.

Omeros Trading Up 1.6 %

Shares of Omeros stock opened at $9.33 on Friday. The stock has a market capitalization of $540.67 million, a price-to-earnings ratio of -4.04 and a beta of 2.01. The firm’s 50-day moving average price is $9.35 and its two-hundred day moving average price is $6.01. Omeros has a 1-year low of $2.61 and a 1-year high of $13.60.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in OMER. BNP Paribas Financial Markets grew its position in shares of Omeros by 130.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock worth $49,000 after buying an additional 7,016 shares during the period. Seros Financial LLC bought a new stake in Omeros in the fourth quarter valued at approximately $159,000. MML Investors Services LLC raised its holdings in Omeros by 19.2% in the third quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company’s stock worth $74,000 after purchasing an additional 3,000 shares during the period. SPC Financial Inc. bought a new position in shares of Omeros during the third quarter worth $77,000. Finally, SG Americas Securities LLC acquired a new position in shares of Omeros in the 3rd quarter valued at $80,000. Institutional investors and hedge funds own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.